China Gives Greenlight to Allergan's XEN? Registration for the Surgical Management of Refractory Glaucoma
-- XEN??Becomes the First Medical Product Approved by Using Real World Evidence inChina -- DUBLIN, April 2, 2020 /PRNewswire/ --?Allergan plc (NYSE: AGN) today announced China's National Medical Products Administration (NMPA) approved the registration of Allergan's XEN? Gel Stent on March 26, 202...
Allergan Voluntarily Recalls BIOCELL? Textured Breast Implants and Tissue Expanders
DUBLIN, July 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced a voluntary worldwide recall of BIOCELL? textured breast implants and tissue expanders. Allergan is taking this action as a precaution following notification of recently updated global safety information concerning the...
Allergan Suspends Sales and Withdraws Supply of Textured Breast Implants in European Markets
-?Action Being Taken Following CE Mark Expiration and Compulsory Recall Request by Agence Nationale de Securite du Médicament (ANSM) - DUBLIN, Dec. 19, 2018 /PRNewswire/ --?Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that the company has suspended sales ...
Allergan Announces Plans to Build First Medical Aesthetics Innovation Center in Chengdu China
-- Innovation Center to Feature State-of-the-Art Medical Aesthetics Training Center for Practitioners, Education and Experience Center for Consumers -- Allergan Expects to Train 3,000 Medical Aesthetics Practitioners Per Year Through New Center -- Announcement Follows Recent Memorandum of Unders...
Ozurdex(R) (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion
-- An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii -- DUBLIN, March 22, 2018 /PRNewswire/ --?Today, Allergan plc (NYSE:AGN) announces the launch of Ozurdex? (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of adult patients...
Allergan's BELKYRA? (Deoxycholic Acid) Receives Marketing Authorisation In Sweden For The Treatment Of Moderate To Severe Fullness Under The Chin (Double Chin)
DUBLIN, Oct. 13, 2016 /PRNewswire/ -- Allergan plc?(NYSE: AGN) a leading global pharmaceutical company, announced thatSweden has received the Marketing Authorisation for BELKYRA? (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA). BELKYRA? is a prescripti...
New Global Research From Allergan Shows New Attitude To Beauty As Women Seek Confidence Over Youth
DUBLIN, June 28, 2016 /PRNewswire/ --?Allergan plc?(NYSE: AGN), a global medical aesthetics company and the makers of Juvéderm? facial fillers today announces the results of a new global beauty trends study. It reveals women are more aware and open to aesthetic enhancement and are taking control ...
